FibroBiologics FBLG 深 滬
等待開盤 09-25 09:30:00 美东时间
1.375
+0.045
+3.38%
華盛通- 最 高1.4699
- 今 開1.35
- 成交量 20.37万股
- 最 低 1.33
- 昨 收 1.33
- 總市值 956.55万
- 52周最高 11.40
- 市盈率 靜 --
- 換手率 2.93%
- 52周最低 0.6201
- 委 比 -5.15%
- 總股本 695.67万
- 歷史最高 1100.00
- 量 比 2.09
- 振 幅 10.52%
- 歷史最低 1.33
- 每 手 1
- 風險率 3.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FibroBiologics Completes ATM Private Placement Of 298,508 Shares And Warrants At $1.675 Per Unit To Its Chief Scientific Officer
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today annou...
09-17 20:41
FibroBiologics Announces Insider Private Placement Financing
FibroBiologics, Inc. ( ($FBLG) ) just unveiled an announcement. On September 15...
09-15 19:49
FibroBiologics Secures US Patent For Therapeutic Use Of Fibroblasts For Use In Wound Healing
Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived Materials to Treat and Accelerate the Healing of Wounds HOUSTON, Sept. 3, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ p...
09-03 20:37
FibroBiologics Releases Third cGMP CYWC628 Drug Product Batch For Shipment To Australia, Supporting Ongoing Phase 1/2 Diabetic Foot Ulcer Trial
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today annou...
08-27 20:34
FibroBiologics Regains Compliance with Nasdaq Trading Rules
HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending wi...
08-26 20:30
FibroBiologics Appoints Leigh Steinberg to Board of Directors
Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins Board HOUSTON, Aug. 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBio...
08-24 20:30
FibroBiologics' Preclinical Trial Of Degenerative Joints Demonstrates Chondrocyte Spheroids Repairs Cartilage
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a breakthro...
08-18 20:39
FibroBiologics Says USPTO Issues US Patent Entitled Methods And Compositions For Treatment Of Type 1 Diabetes Using Fibroblasts In Facilitation Of Islet Engraftment
Patent has potential for applications beyond diabetes, including other cell and tissue transplantation procedures HOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on ...
08-11 20:39
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
FibroBiologics 2026年第二季度财报：净亏损410万美元，CYWC628进入临床
FibroBiologics（FBLG）2026年第二季度净亏损约410万美元，研发费用降至170万美元，期末现金约350万美元；CYWC628已启动患者给药，预计下半年公布中期结果。
08-05 06:13
